The Research Pharmacy opened in the fourth quarter of 1993 and has since provided support for the rapidly expanding clinical research activity at CINJ. Its development parallels that of the Clinical Research Office, and together these shared resources provide the critical support for the high-quality clinical research at CINJ. Dr. Goodin has been the director of the Research Pharmacy from the time of its inception. Since the last submission of the CCSG, the Research Pharmacy operated through institutional funds and chargebacks. During this time, the young investigators in the CINJ Clinical Investigations Program acquired peer- reviewed grant support (R03, R01, R21, Komen Foundation, etc.,) and the Protocol Review and Monitoring System was approved. With the growth of the clinical research activity at CINJ, the usage of this shared resource grew and now meets the criterion for shared resource funding in that a significant portion of usage of this resource is through peer-reviewed, funded project. The overall goal of this shared resource is to support CINJ member clinical research by providing research pharmacy services. The specific objectives of this shared resource are as follows: 1. To develop and maintain appropriate methods for handling investigational agents. 2. To expedite procurement, provide secure storage, and ensure that investigational agents are used according to protocol guidelines. 3. To provide expert consultation on the use of new agents with regard to drug interactions, sequencing, formulation, and safety. 4. To assist CINJ investigators in meeting all regulatory agencies' requirements for drug accountability, and for reporting adverse events. 5. To provide quality assurance by checking consents, verifying patient eligibility, reviewing dosage calculations, and checking for potential drug interactions. The Research Pharmacy is used by 15 members, from five CINJ programs, representing three academic departments. CINJ members represent 100% of all users of this shared resource. While this is a new shared resource, total usage is projected to increase dramatically over the course of this grant period because of the growth of the CINJ phase I and pilot studies. This projection is based on the continued increase in patient accrual onto trials (current accrual is approximately 85 patients/quarter), which is currently more than 400% greater than at the time of the submission of the prior CCSG grant. This services of the Research Pharmacy results in a high degree of safety and compliance with research protocols that are approved by the Protocol Review and Monitoring System. The institution has committed the resources to add additional personnel and space as warranted by usage to meet CINJ user demands.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA072720-04
Application #
6403480
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-04-06
Project End
2005-02-28
Budget Start
Budget End
Support Year
4
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Type
DUNS #
622146454
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23

Showing the most recent 10 out of 775 publications